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Background. Delayed graft function (DGF) remains an important problem after kidney transplantation and reduced long-term
graft survival of the transplanted organ. The aim of the present study was to determine if the development of DGF was associated
with a specific pattern of inflammatory gene expression in expanded criteria of deceased donor kidney transplantation. Also, we
explored the presence of correlations between DGF risk factors and the profile that was found. Methods. Seven days after kidney
transplant, a cDNA microarray was performed on biopsies of graft from patients with and without DGF. Data was confirmed by
real-time PCR. Correlationswere performed between inflammatory gene expression and clinical risk factors.Results. Froma total of
84 genes analyzed, 58 genes were upregulated while only 1 gene was downregulated in patients with DGF compared with no DGF
(𝑃 = 0.01). The most relevant genes fold changes observed was IFNA1, IL-10, IL-1F7, IL-1R1, HMOX-1, and TGF-𝛽. The results
were confirmed for IFNA1, IL-1R1, HMOX-1 and TGF-𝛽. A correlation was observed between TGF-𝛽, donor age, and preablation
creatinine, but not body mass index (BMI). Also, TGF-𝛽 showed an association with recipient age, while IFNA1 correlated with
recipient BMI. Furthermore, TGF-𝛽, IFNA1 and HMOX-1 correlated with several posttransplant kidney function markers, such as
diuresis, ultrasoundDoppler, and glycemia.Conclusions.Overall, the present study shows thatDGF is associatedwith inflammatory
markers, which are correlated with donor and recipient DGF risk factors.
1. Introduction
Delayed graft function (DGF) is a frequent event after
kidney transplantation that strongly correlates with a lower
graft survival rate [1]. Although there are several different
definitions among transplant centers and in the literature [2],
the most accepted definition of DGF is the need for dialysis
within one week of transplantation. The reported incidence
of DGF varies from 3.4% in living donor transplants to 31.2%
in expanded criteria or 37.1% in donation after cardiac death
donors [3]. However, the incidence is much higher in our
Center (unpublished data) and in Latin-American Centers
[4].
DGF is an independent risk factor for decreased graft sur-
vival. In the long-term, patients with DGF had a 49% pooled
incidence of acute rejection compared to 35% incidence in
non-DGF patients [1]. Several factors have been ascribed for
the DGF occurrence, such as donor, recipient, and transplant
procedural factors [5]. Among the first factors, increased age,
hypertension, creatinine clearance, vascular sclerosis, weight,
female gender, and nontraumatic death have been described.
The recipient related factors are the presence of a sensitization
state, the ethnicity, proinflammatory cytokines, and themean
arterial pressure.
Based on the strong association between the occurrence
of DGF and the risk of acute rejection, great effort has
been done to understand the pathogenesis, to identify the
risk factors, and to find therapies that tend to diminish the
incidence of DGF. Thus, several immunologic factors and
coagulant mechanisms have been described that influence
the development of DGF [6–8]. However, the cold ischemia
time (CIT) seems to be one of the most important factors
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Table 1: Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Donors Donors
>60 years old or between 50 and 59 years who fulfilled at least 2 of the
following criteria.
(i) History of hypertension
(ii) Stroke as cause of death
(iii) Preablation sCr >1.5mg/dL
(i) IV drugs abuse
(ii) HIV positive
(iii) Kidneys from standard donors
Recipients Recipients
(i) First disease donor kidney transplant
(ii) >18 years
(iii) Signed informed consent
(iv) Panel reactive antibody < 20%
(i) Diabetes mellitus
(ii) Chronic use of steroids
(iii) Pregnant women/lactancy period
(iv) History of cancer or linfoproliferative disorder
that influence the appearance of DGF [9, 10]. Unfortunately,
in our country, the CIT is very high, that is, more than
24 hours. This is in agreement with the 75% incidence of
DGF in our center.Therefore, the correct identification of the
factors that influence DGF, it would benefit understanding
the mechanisms responsible for the phenomenon.
In this study, we used a strategy to identify the influence
that donor and recipient factors have on the inflammatory
mechanisms of the DGF. We performed a microarray-based
gene expression analysis and we examined the inflammatory
markers on kidney biopsies of patientswith andwithoutDGF.
Once the inflammatory markers were identified, correlations
were performed with different donor and recipient DGF
risk factors. We found that up- and downmodulated inflam-
matory markers were differentially correlated with singular
donor and recipient risk factors.
2. Materials and Methods
2.1. Patients and Biopsies. Thirty four kidney transplanted
patients were enrolled for these studies after giving written
informed consent according to the Declarations of Helsinki.
The clinical and research activities being reported are con-
sistent with the Principles of the Declaration of Istanbul as
outlined in the “Declaration of Istanbul on Organ Trafficking
and Transplant Tourism”. Biopsies were obtained 7 days after
transplant betweenDecember 2008 and June 2010.This study
was approved by an Institutional Review Board.
Biopsies were obtained under ultrasound guidance by
spring-loaded needles (ASAP Automatic Biopsy, Microva-
sive, Watertown, MA). Patients were grouped according to
the presence of DGF. Posttransplant hemodialysis require-
ment was used to define DGF. Table 1 shows the inclu-
sion and exclusion criteria for patients included in this
study and Table 2 shows the clinical characteristics of the
patients enrolled for this study. All patients were treated
with (i) induction therapy of thymoglobulin (7–14 days) and
metilprednisolone (500mg i.v.); (ii) maintenance immuno-
suppression with sirolimus (8–12 ng/mL), mycophenolate
sodium (1440mg), and prednisone (4mg/day); (iii) prophy-
lactic treatment of Ganciclovir IV (GCV-iv) 5mg/kg/day
or Valganciclovir (VGCV) 900mg/day and trimethoprim-
sulphamethoxazole (TMP-SMX).
2.2. Real-Time PCR Microarray Analysis. RNA was isolated
by a phenol-based method from kidney biopsies by homoge-
nization in 5mL of TRIzol (Invitrogen, Carlsbad, CA). RNA
was cleaned up with SABiosciences RT2-qPCR-Grade RNA
isolation kit. The concentration and purity of RNA were
determined by measuring the absorbance in a spectropho-
tometer. Sample dilutions were measured in 10mM Tris at
pH 8. Absorbance A260/A230 ratio was greater than 1.7 and
A260/A280 was greater than 2.0 in all samples analyzed. Also
an aliquot of each RNA sample was run on a denaturing
agarose gel and sharp bands were present for both the 18S
and 28S ribosomal RNA. Samples were discarded if signals
of RNA degradation were observed in the agarose gel such
as smearing or shoulders on the RNA peaks. RNA samples
(1 𝜇g) were reverse-transcribed into cDNAs using a first-
strand cDNART kit (SABioscience, CA).Then, samples were
analyzed according to the manufacturer’s recommendations
using the “Innate & Adaptive Immune Responses” array in
conjunction with the RT2 Profiler PCR Array System from
SuperArray Bioscience (catalog number: PAHS-052Z, Fred-
erick, MD). A total of 84 inflammatory related genes were
examined (see Table 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2014/167361). The array
was initially performed with 16 RNA from kidney biopsies
samples. For this, real-time PCR was performed using a 96-
well format PCR array and an Applied Biosystems 7500 real-
time PCR unit. Primers for all genes for real-time PCR of the
microarray analysis had been pretested and confirmed by the
manufacturer. Assay includes positive and negative controls
as well as three sets of housekeeping genes for normalization
purposes. Analysis of real-time PCR results is based on
the ΔΔCt method with normalization of the raw data to
housekeeping genes. Data were analyzed using the web-based
PCR array data analysis software (SABiosciences). A 2-fold
cut off threshold was used to define up or downmodulation
of the genes analyzed.
2.3. Real-Time PCR. The result of the microarray was ana-
lyzed for confirmation by using a SYBR Green-based real-
time PCR. Briefly, RNA samples from 11 no DGF and 23 DGF
patients were tested for IL-1R1, IL-10, IL-1F7, IFNA1, HMOX-
1, and TGF-𝛽 gene expression using the qPCR SuperMix
Universal (Invitrogen, CA). Reaction solutionswere prepared
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Table 2: Characteristics of renal transplant patients.
Group 1
(DGF, 𝑛 = 23)
Group 2
(No DGF, 𝑛 = 11) 𝑃 values
Recipient age (years) 54.7 ± 8.2 50.1 ± 16.1 0.27
Recipient BMI 25.7 ± 4.3 23.5 ± 1.3 0.10
Time of dialysis (years) 4.8 ± 3.9 5.67 ± 2.7 0.51
HLA MM (A, B, DR) 3 ± 1.7 3.4 ± 1.1 0.48
CIT (hours) 25.2 ± 3 23.9 ± 5.5 0.37
Donor age (years) 56.4 ± 4.8 56.8 ± 4.6 0.81
Donor BMI 26.9 ± 4.2 27.9 ± 5.3 0.55
Preablation creatinine (mg/dL) 1.8 ± 0.7 1.3 ± 0.3 0.03
Day 1 diuresis (L) 0.37 ± 0.5 2.7 ± 2.5 0.0001
Day 1 Eco Doppler 0.81 ± 0.6 0.73 ± 0.09 0.66
Day 1 uremia (mg/dL) 126.5 ± 27.4 119.1 ± 26.9 0.46
Day 1 creatinine(mg/dL) 7.62 ± 2 9.08 ± 1.5 0.039
Day 1 serum Na+ (mEq/L) 136.4 ± 3 135.2 ± 2.8 0.27
Day 2 diuresis (L) 0.45 ± 0.56 3.2 ± 2.3 0.0001
Day 2 uremia (mg/dL) 142.9 ± 28 137.9 ± 31.2 0.64
Day 2 creatinine (mg/dL) 8.05 ± 2.2 8.52 ± 1.1 0.52
Day 2 serum Na+ (mEq/L) 135.7 ± 2.7 136.2 ± 2.4 0.60
BMI: body mass index; HLA MM: human leukocyte antigen mismatch.
using reagents from the one-step SYBR Green Quantitative
RT-PCR kit (Invitrogen, CA) combined with 0.25𝜇Mof each
primer and 1 𝜇g of total RNA.The settings for the PCR instru-
ment were as follows: 42∘C for 30min, 94∘C for 2min, and 40
cycles of 95∘C for 15 s followed by 60∘C for 1min. Fluorescent
signals were monitored sequentially for each sample tube
once per cycle at the end of the elongation step.The specificity
of the RT-PCR products was confirmed by analysis ofmelting
curves and by omission of the reverse transcriptase. Human
𝛽-actin gene expression from the same RNA sample was also
tested for normalization and quantification. The result was
expressed as the fold expression normalized to 𝛽-actin. The
gene expression was considered not detectable if the ratio of
the gene against 𝛽-actin was smaller than 0.001. The data of
the undetectable gene, was not plotted in Figures 3 and 4.
2.4. Statistical Analyses. For PCR array data analysis we used
the SABiosciences RT2 Profiler Data Analysis Software to
determine gene expression profiles (http://pcrdataanalysis
.sabiosciences.com/pcr/arrayanalysis.php), which deter-
mined fold regulation values for each gene using the relative
quantification 2-ΔΔCt method. ΔCt values were normalized
using the mean values of three housekeeping genes: 𝛽-Actin,
𝛽-2-microglobulin, and GAPDH. All wells with a Ct value
above 35 cycles were excluded from the analysis. This left
84 transcripts for analysis. Mann Whitney tests were used
to compare means of continuous variables. Nonparametric
test with Spearman’s rank correlation coefficient was used
for analyzing correlation. A 𝑃 value <0.05 was considered
significant. Graphs were generated by GraphPad Prism
(GraphPad, Inc., La Jolla, CA).
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Figure 1: Scatter plot analysis of gene expression profiling on
expanded criteria of kidney transplant patients. cDNA microarray
analysis on 16 RNA samples from kidney transplant patients. After
normalization on housekeeping genes, the final scores of each of the
genes of all arrays were compared with those from the control array.
The scatter plot was acquired as described inMaterials andMethods.
The 𝑦-axis represents log scores from DGF patients (group 1) and
the 𝑥-axis represents log scores from no DGF patients (group 2).
Each symbol represents one gene.Those gene outside the boundaries
represent 2-fold higher or lower expressed in DGF patients.
3. Results
3.1. Microarray. Quantitative real-time PCR microarray was
used to analyze the gene expression profile in biopsy sam-
ples of 16 expanded criteria kidney transplant patients.
We analyzed and compared the inflammatory genes profile
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Figure 2: Real-time PCR results evaluatingmRNA levels of inflammatory pathway related genes in kidney transplant patients. IL-1R1, IFNA1,
HMOX-1, TGF-𝛽, IL-10, and IL-1F7 were assayed by real-time PCR in whole kidney RNA samples from no DGF patients and DGF patients.
Values were normalized to the level of 𝛽-actin RNA. Relative expression levels of all genes were calculated as 2∧[(Ct reference gene) − (Ct
target gene)]. ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 by MannWhitney test.
between DGF (𝑛 = 8) and no DGF (𝑛 = 8) patients.
Supplementary Table 2 shows a summary of the clinical
characteristics of the patients enrolled for the microarray
study. Seven day posttransplant kidney biopsies samples
were used to perform the assay. From a total of 84 genes
analyzed, 58 genes were upregulated while only 1 gene
was downregulated in kidney biopsies from patients with
DGF compared with no DGF (Figure 1). The most relevant
genes upregulated, at least by two- or more-fold were IL-
1R1, IL-10, IFNA1, IL-1F7, and HMOX-1 (Table 3). On the
contrary, only TGF-𝛽 was downmodulated in DGF patients
(Table 3). In order to confirm the results obtained with the
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Figure 3: Correlation between the gene expression levels and recipient and donor risk factors. Correlation between donor age and TGF-𝛽
(a), preablation creatinine and TGF-𝛽 (b), recipient age and TGF-𝛽 (c), and recipient BMI and IFNA-1 (d). Regression lines are shown in each
figure with correlation coefficients (𝑅2) and 𝑃 values.
microarray, we then performed real-time PCR for these
genes. For this confirmation assay, we used a total of 34
biopsies samples (11 no DGF and 23 DGF patients). Although
we were not able to detect some of the genes in all biop-
sies samples analyzed, the results obtained with the real-
time PCR assay confirmed that IL-1R1 (Figure 2(a)), IFNA1
(Figure 2(b)) and HMOX-1 (Figure 2(c)) genes were upreg-
ulated and TGF-𝛽 (Figure 2(d)) gene was downregulated in
DGF patients (Figure 1, 𝑃 < 0.01). However, we were unable
to show statistical differences in IL-10 (Figure 2(e)) and IL-
1F7 (Figure 2(f)) genes between groups of patients analyzed.
3.2. Correlations between Gene Expression and Clinical Fea-
tures. To further determine if the changes in gene expression
observed in the biopsies could be related to donor specific
characteristics, CIT, or recipients features we analyzed cor-
relations between genes expression and clinical parameters.
The donor specific characteristics analyzed were the age,
preablation creatinine and the body mass index (BMI).
Correlations were performed with the genes that were up-
and downmodulated. We did not find any correlation with
donor BMI. However, we found a correlation between TGF-𝛽
gene expression with donor age (Figure 3(a)) and preablation
creatinine (Figure 3(b)).Then, the correlations were analyzed
betweenCIT and genes expression. Although, we did not find
statistical significant correlations between this risk factor and
inflammatory markers, we found a trend between IFNA1 and
CTI (𝑃 = 0.057; data not shown). Following this, the analysis
was performed with recipient characteristics, such as age,
BMI, and time on dialysis. We did not find correlations with
time on dialysis. However, we found that TGF-𝛽 expression
inversely correlated with recipient age (Figure 3(c)). Also,
there was a positive correlation between IFNA1 and recipient
BMI (Figure 3(d)). Finally, the correlations were examined
with markers of kidney function during the first two days
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Figure 4: Correlation between the gene expression levels and kidney functional parameters. Correlation between Eco Doppler index of day
1 and IFNA1 (a), diuresis of day 1 and IFNA1 (b), glycemia of day 2 and HMOX-1 (c), diuresis of day 2 and TGF-𝛽 (d), glycemia of day 1 and
TGF-𝛽 (e), and Eco Doppler index of day 1 and TGF-𝛽 (f). Regression lines are shown in each figure with correlation coefficients (𝑅2) and 𝑃
values.
after the transplant. When IFNA1 was analyzed, a positive
and negative correlation was observed with the Doppler
ultrasound resistive index and diuresis, respectively (Figures
4(a) and 4(b)). Furthermore, for HMOX-1 a positive cor-
relation was observed with glycemia (Figure 4(c)). Finally,
for TGF-𝛽 we found a positive correlation with diuresis
(Figure 4(d)) and the amount of units of insulin administered
(𝑃 = 0, 001; data not shown) to the patients, while negative
correlation was observed with glycemia (Figure 4(e)) and
Doppler ultrasound resistive index (Figure 4(f)).
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Table 3: Real-time PCRmicroarray: genes up- and downmodulated
in kidney biopsies from DGF versus no DGF patients.
Mediators Fold change
Upregulation
IL-1R1 4.9
IL-10 4.8
IFNA1 4.4
IL-1F7 4.3
HMOX-1 2.9
Downregulation TGF-𝛽 3.3
4. Discussion
Sometimes a biopsy is performed at the time of transplan-
tation in order to check for preexisting lesions in the donor
kidney. However, it has not been helpful as an indicator for
therapeutic intervention. Recent findings suggest the impor-
tance of recipient factors in addition to the donor factors [5].
In this study we performed a 7 day posttransplant biopsy that
should reflect both donor and recipient factors, although the
interpretation of the data requires a comprehensive analysis
because multiple factors are involved.
A systematic biological assessment of these molecular
changes suggests that the inflammatory process driven by
ischemia reperfusion injury (IRI) is largely responsible for
DGF occurrence. The analysis of the microarray shows that
several inflammatory mediators are upregulated in DGF
patients.Themost significantmediators but not the only ones
were IL-R1, IL-10, IFNA1, IL-1F7, and HMOX-1. However,
only IFNA1, IL-1R1, and HMOX-1 were confirmed to differ
between DGF and no DGF group by real-time PCR. It
is important to mention that the partial selection of the
mediators analyzed for confirmation with the real-time PCR
was chosen based on the fold changes that we found in the
microarray.
It is known that drugs used for immunosuppression may
affect DGF and gene expression profile [11]. For example, it
has been described that sirolimus prolongs recovery from
delayed graft function after cadaveric renal transplantation
[12]. In our study, biopsies were obtained before the introduc-
tion of sirolimus in the immunosuppressive regime. There-
fore, gene expression data was not influenced by sirolimus.
It is important to mention that in this study, the differential
gene expression profile between DGF and no DGF patients
was not influenced by immunosuppression drugs, since all
patients received the same immunosuppressive regime.
Based on the function of each IFNA1 and IL-1R1, we can
speculate that the pattern of cytokines upregulated was com-
patible with a proinflammatory state. For example, IFNA1
has a well-known antiviral action and also plays a major role
in the adaptive immune response acting on dendritic cells,
NK cells, and lymphocytes [13, 14]. Furthermore, IL-1R1 is a
signaling receptor for IL-1. This cytokine is a potent factor
with pleiotropic functions such as stimulating angiogenesis
at inflamed tissue sites, triggering proinflammatory cytokine
and contributing to the polarization of Th17 cells [15]. The
upregulation of IL-1R1 observed in biopsies of DGF patients
suggests that this kidney may be more suitable to respond
under inflammatory microenvironments, where the IL-1 is
present.
In agreement with this proinflammatory microenviron-
ment, we found that TGF-𝛽 is downmodulated in DGF
patients. TGF-𝛽 is a 25-kDa homodimeric peptide with
pleiotropic activity on different cell types [16].Their immuno-
suppressive effects are known by inhibiting lymphocyte acti-
vation, but also proinflammatory activity has been described
[16, 17]. Moreover, recent studies suggest that high levels of
TGF-𝛽 activated T cells that cause cytotoxic damage and
acute rejection [18]. However, also a low TGF-𝛽 production
in both the donor and recipient was associated with risk for
early rejection and worse graft function at 4 years [18].
HMOX-1 is another mediator that is upregulated in
DGF patients. HMOX-1 is a very important enzyme which
degrades heme into carbon monoxide, biliverdin, and free
iron [19, 20]. The expression of HMOX-1 is inducible in
response to pathophysiological stresses and it has antioxidant,
anti-inflammatory, and antiapoptotic activity [19, 20]. In fact,
the expression of HMOX-1 protects from the induction of
chronic allograft rejection [21, 22]. Also, it has been described
that TGF-𝛽 induces HMOX-1 [23]. However, since TGF-𝛽
is downmodulated in our study, we believe that HMOX-1
upregulation is due to the proinflammatory microenviron-
ment. Perhaps, the high levels of HMOX-1 may act as feed-
back mechanisms that tend to control the proinflammatory
state.
Differences between no DGF and DGF groups were also
seen in long-termoutcome such as patients’ survival and graft
function (data not shown), as was expected. At three years
after kidney transplant, 91% of the patients of the no DGF
group were alive and with a good kidney function; however
with the no DGF group 74% were alive with normal kidney
function.
The findings in biopsies taken at seven days are the
results of factors contributed by the donor (such as age,
BMI, and preablation creatinine), the procurement period
(CIT, preservation liquid), the receptor (age, BMI), and early
posttransplant period (ischemia reperfusion injury). In fact,
there are much more factors that influence the DGF, such as
immunosuppression therapy [11]. The relative impact of each
of themarkers onDGF is difficult to assess.However, by using
the inflammatory markers as the endpoint and performing
the correlations with each of the factors that contributed
to the DGF, we determined the relative strength of each
factor on the inflammatory process. Of the donor derived
factors analyzed, donor age and preablation creatinine were
associated with TGF-𝛽. Since preablation, creatinine reflects
the state of the kidney to be engrafted; this association with
TGF-𝛽 could be expected. Surprisingly, we did not find a
significant correlation with CIT as was described in [24], but
we did find a trend with IFNA1 (𝑃 = 0, 057; data not shown).
Perhaps, the fact that there was not difference in CIT between
groups (Table 2) underscores this result. Of the recipient
derived factors, the age was associated with TGF-𝛽, while the
BMI with IFNA-1. Thus, recipient factors act both on pro-
and anti-inflammatory mediators. Based on the link between
adipose tissue and inflammation [25] we can speculate that
obesity influences more over the proinflammatory markers,
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while the recipient age decreases the anti-inflammatory
marker. The result of the recipient factors is to shift the
balance to a proinflammatory state. However, it seems that
the donor factors influence the inflammation by decreasing
the immunosuppressive cytokine, such as TGF-𝛽.
Finally, we found more correlations at the posttransplant
period, more precisely with kidney function markers. Some
of them may be ascribed to the IRI. For example, the
association between IFNA-1 with diuresis and ultrasound
Doppler, HMOX-1 with and glycemia, and TGF-𝛽 with
diuresis, ultrasound Doppler, glycemia, and units of insulin
administrationmight represent the sumof the factors derived
from the donor and the recipient plus the reperfusion injury.
Gene array has been used before in kidney transplanta-
tion [26, 27]. Most of them were used to monitor the graft
status, infection, or graft rejections. Despite the high cost of
the technique, by performing the gene array we may detect
biomarkers that allow us to predict the outcome of the graft.
5. Conclusion
Our results identify inflammatory molecular changes in
kidney transplant ofDGFpatients that associateswith clinical
risk factors.The strength of these factors on the inflammatory
process is uneven. Overall, these results suggest for the first
time that changes in some inflammatory mediators in kidney
transplantation recipients may be ascribed to donors while
others to the recipients’ characteristics.
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